Protagonist Therapeutics (PTGX) Interest & Investment Income (2015 - 2026)

Protagonist Therapeutics has reported Interest & Investment Income for 12 years, with the latest figure at $5.9 million in Q1 2026.

• Quarterly Interest & Investment Income fell 22.41% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.1 million (down 8.2% YoY) and the FY2025 annual result came in at $28.8 million, up 9.4% from the prior year.
• Interest & Investment Income retreated to $5.9 million in Q1 2026 per PTGX's latest filing, from $6.8 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $7.7 million in Q3 2024 and troughed at $168000.0 in Q1 2022.
• A 5-year average of $4.7 million and a median of $4.4 million in 2024 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2026: Interest & Investment Income soared 1745.08% in 2022, then retreated 22.41% in 2026.
• Over 5 years, Interest & Investment Income stood at $2.3 million in 2022, then surged by 88.45% to $4.2 million in 2023, then jumped by 61.55% to $6.9 million in 2024, then declined by 1.34% to $6.8 million in 2025, then retreated by 13.09% to $5.9 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $5.9 million, $6.8 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.